Login to Your Account

Other News To Note

Friday, January 25, 2013
Genentech, of South San Francisco, a member of the Roche Group, said the FDA gave its go-ahead to a new use of already approved cancer drug Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription